Sort by
Keyphrases
Acute Lymphoblastic Leukemia
83%
Signal Transduction Inhibitors
38%
IKZF1
37%
Childhood Acute Lymphoblastic Leukemia
35%
ETV6-RUNX1
33%
Secondary Lesions
33%
Intrachromosomal Amplification of Chromosome 21 (iAMP21)
33%
IKZF1 Deletion
33%
Hyperdiploid
33%
Prognostic Effect
33%
Minimal Residual Disease
25%
Relapse Risk
11%
Gene Alteration
11%
Survival Rate
9%
Event-free Survival
8%
Bother
7%
BCP-ALL
7%
SH2B3
7%
FMS-like Tyrosine Kinase 3 (FLT3)
7%
Leukemia Patients
6%
Cell Signaling
5%
Clinical Impact
5%
Novel Therapies
5%
Energy Conservation
5%
Normal Function
5%
Distinct Subtypes
5%
Coding Genes
5%
Transcription Factor
5%
Lymphocyte Development
5%
Malignancy
5%
Antileukemic Drugs
5%
Risk-adapted Therapy
5%
Targeted Drugs
5%
Ruxolitinib
5%
FLT3 Inhibitor
5%
Gilteritinib
5%
CRLF2
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Chromosome 21
33%
Minimal Residual Disease
33%
Survival Rate
11%
Gene Mutation
11%
Event Free Survival
11%
B Cell
7%
Precursor
7%
Signal Transduction
5%
Risk Stratification
5%
Proportional Hazards Model
5%
Lymphocyte Development
5%
Prognostic Factor
5%
Transcription Factors
5%
Hazard Ratio
5%
Cancer
5%
Recurrence Risk
5%
Immunotherapy
5%
Leukocyte
5%
Genetic Risk
5%
Cell Count
5%
Autosome
5%
Ruxolitinib
5%
Gilteritinib
5%
Biochemistry, Genetics and Molecular Biology
RUNX1
33%
ETV6
33%
Chromosome 21
33%
IKZF1
33%
SH2B3
7%
Precursor
7%
B Cell
7%
Event Free Survival
7%
Ruxolitinib
5%
CRLF2
5%
Autosome
5%
